Humacyte, Inc. (HUMAW)

Every figure this model derived for HUMAW, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 367,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 79,903,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 92,787,000 AssetsCurrent 2026-06-30
current liabilities 14,948,000 LiabilitiesCurrent 2026-06-30
equity 31,261,000 StockholdersEquity 2026-06-30
interest expense 10,297,000 InterestExpenseNonoperating 2026-06-30
ocf -97,193,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 2,121,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 10,709,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up HUMAW on one particular measure came for.

RatioValue
current ratio6.21
current ratio reported6.21
dilution pct33.52
interest cover-10.8
revenue growth159.29
revenue growth per share94.2
roic-500.71
rule of 40-5081.49
sbc pct revenue504.9

What to be careful about

What this model itself distrusts about HUMAW's figures. Written by the derivation as it ran, not added afterwards.